Yadong Huang, Ph.D., doctoral supervisor and distinguished professor of Pearl River Scholars. Senior visiting scholar of Rockefeller University, USA, and senior visiting scholar of Harvard Medical School. Yadong Huang is currently the deputy dean of the Institute of Biomedicine of Jinan University; the director of the Guangdong Provincial Key Laboratory of Bioengineering Drugs; the honorary director/chief scientist of the Medical Biotechnology Research and Development Center of Jinan University; and the chairman of the National Engineering Research Center for Genetically Engineered Drugs. He has long been engaged in the research into and development of recombinant protein and peptide drugs and related biological products. He has achieved excellent results in drug development and cosmeceutical product development, represented by repair factors; successively produced two new genetically engineered class I drugs, two new clinically approved biological agents, and a genetically modified biological product; and participated in the research and development of national class III drug devices.
Yadong Huang, Ph.D., doctoral supervisor and distinguished professor of Pearl River Scholars. Senior visiting scholar of Rockefeller University, USA, and senior visiting scholar of Harvard Medical School. Yadong Huang is currently the deputy dean of the Institute of Biomedicine of Jinan University; the director of the Guangdong Provincial Key Laboratory of Bioengineering Drugs; the honorary director/chief scientist of the Medical Biotechnology Research and Development Center of Jinan University; and the chairman of the National Engineering Research Center for Genetically Engineered Drugs. He has long been engaged in the research into and development of recombinant protein and peptide drugs and related biological products. He has achieved excellent results in drug development and cosmeceutical product development, represented by repair factors; successively produced two new genetically engineered class I drugs, two new clinically approved biological agents, and a genetically modified biological product; and participated in the research and development of national class III drug devices.